BioCentury | Apr 1, 2020
Distillery Therapeutics

Targeting the NCK1-WIPF1 interaction for enteropathogenic E. coli infection

...Wang, Changzhou University, Changzhou, China email: minuswan@163.com CONTACT: Yong-Qiang Li, Shandong University, Jinan, China email: lyq@suda.edu.cn...
BioCentury | Nov 19, 2019

A vaccine made of red blood cell and tumor cell membranes plus checkpoint blockade for breast cancer, melanoma

...Wang, Soochow University, Suzhou, China email: cwang@suda.edu.cn CONTACT: Zhuang Liu, same affiliation as above email: zliu@suda.edu.cn...
BioCentury | Jul 10, 2019
Distillery Therapeutics

A hydroxypyridinone as chelation therapy for uranium exposure

...published online June 25, 2019 doi:10.1038/s41467-019-10276-z CONTACT: Juan Diwu, Soochow University, Suzhou, China email: diwujiuan@suda.edu.cn...
...Zhou, same affiliation as above email: ruhongz@us.ibm.com CONTACT: Shuao Wang, same affiliation as above email: shuaowang@suda.edu.cn Claire...
BioCentury | May 9, 2018
Distillery Techniques

Drug delivery

...published online April 23, 2018 doi:10.1073/pnas.1712963115 CONTACT: Lichen Yin, Soochow University, Suzhou, China email: lcyin@suda.edu.cn...
BioCentury | Nov 17, 2017
Clinical News

RedHill's Bekinda meets in Phase II for IBS-D

...patients with irritable bowel syndrome with diarrhea (IBS-D) showing that once-daily 12 mg oral Bekinda ondansetron...
...III GUARD trial (see BioCentury, June 30 ). Bekinda is a once-daily, extended-release tablet of ondansetron...
...Bekinda ondansetron (RHB-102) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Once-daily, extended-release tablet of ondansetron...
BioCentury | Nov 8, 2017
Distillery Techniques

Drug platforms

...published online Oct. 30, 2017 doi:10.1172/JCI95109 CONTACT: Kesheng Dai, Soochow University, Suzhou, China email: kdai@suda.edu.cn Mark...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...to severe acute post-operative pain Submit NDA 3Q17 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Bekinda ondansetron...
BioCentury | Jun 30, 2017
Clinical News

RedHill's Bekinda meets in Phase III gastroenteritis trial

...patients ages >12 with acute gastroenteritis and gastritis showing that once-daily oral 24 mg Bekinda ondansetron...
...October to discuss an NDA for the product. Bekinda is a once-daily, extended-release tablet of ondansetron...
...Bekinda ondansetron (RHB-102) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Once-daily, extended-release tablet of ondansetron...
BioCentury | Apr 7, 2017
Finance

To market, to market

...to severe acute postoperative pain Submit NDA Mid-2017 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) Bekinda ondansetron...
BioCentury | Mar 28, 2017
Distillery Techniques

Drug delivery

...of Applied Chemistry, Changchun, China email: xschen@ciac.ac.cn CONTACT: Lichen Yin, Soochow University, Jiangsu, China email: lcyin@suda.edu.cn...
Items per page:
1 - 10 of 165